EVH - Evolent Health Inc Stock Price, Fair Value and News

28.32USD-0.94 (-3.21%)Market Closed

Market Summary

USD28.32-0.94

Market Closed

-3.21%

EVH Alerts

JPMORGAN CHASE & CO reported owning 4% of EVH [2024-04-09]

EVH Stock Price

View Fullscreen

EVH RSI Chart

EVH Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-28.92

Price/Sales (Trailing)

1.66

EV/EBITDA

-148.2

Price/Free Cashflow

22.93

EVH Price/Sales (Trailing)

EVH Profitability

Operating Margin

23.45%

EBT Margin

-10.31%

Return on Equity

-10.59%

Return on Assets

-4.22%

Free Cashflow Yield

4.36%

EVH Fundamentals

EVH Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

45.4%

Rev. Growth (Qtr)

8.81%

EVH Earnings

Earnings (TTM)

-113.0M

Earnings Growth (Yr)

-194.4%

Earnings Growth (Qtr)

-31.93%

Breaking Down EVH Revenue

Last 7 days

-1.3%

Last 30 days

-9.7%

Last 90 days

-2.2%

Trailing 12 Months

-17.1%

How does EVH drawdown profile look like?

EVH Financial Health

Current Ratio

1.01

Debt/Equity

0.56

Debt/Cashflow

0.24

EVH Investor Care

Shares Dilution (1Y)

3.94%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.5B	1.6B	1.8B	2.0B
2022	989.9M	1.1B	1.2B	1.4B
2021	918.5M	923.2M	906.1M	908.0M
2020	869.9M	895.2M	914.6M	924.6M
2019	685.1M	732.8M	803.0M	846.4M
2018	468.4M	505.7M	547.7M	627.1M
2017	311.0M	361.5M	409.2M	434.9M
2016	146.3M	192.4M	212.2M	254.2M
2015	0	49.4M	73.1M	96.9M
2013	0	0	0	25.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Evolent Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 02, 2024	mccarthy daniel joseph	sold (taxes)	-194,004	34.41	-5,638	president
Mar 02, 2024	johnson john paul	sold (taxes)	-310,378	34.41	-9,020	chief financial officer
Mar 02, 2024	weinberg jonathan	sold (taxes)	-166,200	34.41	-4,830	general counsel
Mar 01, 2024	johnson john paul	acquired	-	-	12,123	chief financial officer
Mar 01, 2024	shams aammaad	sold (taxes)	-88,399	34.41	-2,569	chief accounting officer
Mar 01, 2024	mccarthy daniel joseph	acquired	-	-	19,398	president
Mar 01, 2024	weinberg jonathan	acquired	-	-	21,822	general counsel
Mar 01, 2024	mccarthy daniel joseph	sold (taxes)	-454,556	34.41	-13,210	president
Mar 01, 2024	blackley seth	sold (taxes)	-826,012	34.41	-24,005	chief executive officer
Mar 01, 2024	glass russell monroe	acquired	-	-	1,163	-

Which funds bought or sold EVH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	HMS Capital Management, LLC	added	7.82	15,990	243,269	0.14%
Apr 24, 2024	BROWN ADVISORY INC	unchanged	-	-8,849	1,208,970	-%
Apr 24, 2024	IMA Wealth, Inc.	reduced	-4.46	-66,924	1,232,680	0.58%
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	-177	24,101	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.41	-402,000	123,000	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-72.00	9,837	-%
Apr 23, 2024	Values First Advisors, Inc.	added	10.84	51,899	569,008	0.33%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	336,794	1,917,990	0.01%
Apr 22, 2024	Genesee Capital Advisors, LLC	reduced	-5.2	-74,663	1,193,360	0.65%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-4.97	-43,675	727,741	-%

Are Funds Buying or Selling EVH?

Are funds buying EVH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EVH

No. of Funds

EVH Alerts

JPMORGAN CHASE & CO reported owning 4% of EVH [2024-04-09]

Unveiling Evolent Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	jpmorgan chase & co	4.0%	4,679,353	SC 13G/A
Feb 13, 2024	vanguard group inc	9.41%	10,821,331	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	7.23%	8,313,157	SC 13G
Jan 26, 2024	blackrock inc.	7.3%	8,423,999	SC 13G/A
Jan 18, 2024	jpmorgan chase & co	5.1%	5,863,530	SC 13G/A
Apr 26, 2023	magellan health inc	0%	0	SC 13G/A
Apr 10, 2023	fmr llc	-	0	SC 13G
Mar 08, 2023	upmc	1.97%	2,190,702	SC 13G/A
Feb 14, 2023	granahan investment management, llc	3.12%	3,155,211	SC 13G/A

Recent SEC filings of Evolent Health Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	SC 13G/A	Major Ownership Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	3	Insider Trading

Peers (Alternatives to Evolent Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	455.4B	371.6B	0.31%	-0.92%	20.35	1.23	14.64%	11.24%
CI	103.7B	195.3B	-0.92%	38.85%	19.3	0.53	8.17%	-20.79%
CVS	84.7B	357.8B	-14.21%	-7.01%	10.14	0.24	10.95%	93.52%
HCA	83.0B	65.0B	-2.46%	13.22%	15.84	1.28	7.86%	-7.11%
CNC	40.5B	154.0B	-1.12%	9.99%	14.98	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-1.51%	52.05%	16.84	0.96	4.57%	23.40%
UHS	11.4B	14.3B	-6.67%	17.96%	15.95	0.8	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-4.23%	9.23%	34.28	4.13	6.06%	9.17%
ACHC	6.6B	2.9B	-6.62%	-3.50%	-303.23	2.24	12.20%	-107.93%
AMN	2.1B	3.8B	-8.18%	-34.26%	10.11	0.56	-27.73%	-52.50%
AMEH	2.0B	1.4B	-5.68%	1.59%	33.41	1.46	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-7.02%	-15.70%	23.79	1.4	11.31%	35.83%
BKD	1.3B	3.0B	4.49%	59.95%	-6.87	0.43	6.74%	20.73%
BEAT	54.0M	-	-6.82%	-	-3.69	-	-	-12.94%
AMS	19.1M	21.3M	14.29%	7.64%	35.87	0.9	8.00%	-62.25%

Evolent Health Inc News

Latest updates

Evolent Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	8.8%	556,055,000	511,015,000	469,136,000	427,690,000	382,432,000	352,585,000	319,939,000	297,057,000	248,358,000	222,471,000	222,057,000	215,071,000	246,536,000	239,572,000	217,299,000	221,232,000	236,525,000	220,143,000	191,959,000	197,756,000	193,104,000
Cost Of Revenue	17.5%	454,428,000	386,585,000	351,938,000	310,475,000	299,368,000	266,617,000	249,705,000	219,739,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	9.2%	577,405,000	528,953,000	490,704,000	438,045,000	384,310,000	339,634,000	324,572,000	299,855,000	260,572,000	229,052,000	229,728,000	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	299,855,000	260,572,000	229,052,000	229,728,000	231,016,000	246,804,000	256,020,000	443,128,000	246,323,000	451,120,000	240,281,000	217,192,000	244,402,000	206,456,000
S&GA Expenses	-15.7%	81,428,000	96,567,000	90,389,000	89,726,000	82,861,000	68,521,000	58,955,000	58,932,000	66,917,000	51,292,000	42,699,000	58,591,000	58,663,000	52,366,000	47,296,000	52,087,000	35,870,000	58,808,000	66,932,000	74,838,000	62,923,000
EBITDA Margin	-777.6%	-0.01	0.00	-0.02	-0.03	0.02	0.02	0.05	0.06	0.06	0.05	0.02	-0.19	-	-	-	-	-	-	-	-	-
Interest Expenses	-16.3%	12,238,000	14,614,000	14,458,000	12,895,000	6,429,000	4,754,000	2,148,000	2,241,000	6,447,000	6,367,000	6,274,000	6,337,000	8,338,000	7,416,000	6,290,000	6,281,000	3,743,000	3,630,000	3,620,000	3,562,000	2,000,000
Income Taxes	-163.8%	-14,641,000	-5,550,000	-1,000,000	-68,189,000	1,116,000	-45,500,000	-184,000	1,200,000	-453,000	234,000	91,000	611,000	763,000	503,000	-3,904,000	270,000	-22,848,000	-849,000	1,398,000	-496,000	11,000
Earnings Before Taxes	-55.7%	-48,067,000	-30,874,000	-35,293,000	-88,171,000	-10,227,000	-43,393,000	-4,309,000	-4,148,000	2,600,000	-12,806,000	-9,016,000	-10,579,000	-9,874,000	-36,532,000	-205,917,000	-78,217,000	-223,754,000	-26,587,000	-30,502,000	-49,145,000	-17,540,000
EBT Margin	-12.1%	-0.10	-0.09	-0.11	-0.10	-0.05	-0.04	-0.02	-0.02	-0.03	-0.05	-0.07	-0.29	-	-	-	-	-	-	-	-	-
Net Income	-31.9%	-33,411,000	-25,324,000	-34,323,000	-19,982,000	-11,349,000	2,123,000	-4,588,000	-5,350,000	-5,647,000	-13,040,000	-9,107,000	-9,807,000	822,000	-822,000	-	-	-198,096,000	-25,521,000	-31,615,000	-46,739,000	-16,687,000
Net Income Margin	-13.3%	-0.06	-0.05	-0.04	-0.03	-0.01	-0.01	-0.03	-0.03	-0.04	-0.03	-0.02	-0.01	-	-	-	-	-	-	-	-	-
Free Cashflow	47.7%	89,381,000	60,521,000	-8,503,000	-17,131,000	26,538,000	-12,627,000	4,507,000	-66,599,000	57,499,000	35,344,000	-33,404,000	-57,320,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.4%	2,680	2,670	2,647	2,589	1,817	1,759	1,304	1,339	1,419	1,254	1,293	1,306	1,372	1,392	1,270	1,451	1,498	1,714	1,652	1,629	1,722
Current Assets	7.0%	684	639	577	476	478	394	423	463	524	478	506	508	548	549	275	258	229	308	241	321	488
Cash Equivalents	4.5%	193	185	143	158	188	157	193	210	355	282	238	304	362	371	98.00	68.00	129	97.00	93.00	171	388
Net PPE	-2.1%	78.00	80.00	84.00	89.00	88.00	95.00	93.00	83.00	81.00	82.00	83.00	84.00	86.00	88.00	89.00	86.00	85.00	83.00	80.00	77.00	74.00
Goodwill	-0.1%	1,117	1,118	1,118	1,118	723	723	426	426	426	77.00	349	349	349	349	349	570	566	772	772	770	768
Liabilities	2.6%	1,434	1,398	1,381	1,297	958	903	691	728	726	646	679	688	752	737	623	604	569	590	506	479	533
Current Liabilities	9.6%	674	615	541	458	433	382	343	382	445	367	403	415	403	365	245	236	193	260	173	164	269
Short Term Borrowings	-100.0%	-	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-0.5%	597	600	633	632	413	412	283	283	216	211	207	202	263	285	300	297	294	228	226	223	221
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	27.00	27.00	27.00	27.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-0.5%	597	600	633	632	413	412	283	283	216	211	207	202	263	-	-	-	294	-	-	-	-
Shareholder's Equity	-2.6%	1,068	1,096	1,093	1,122	859	856	613	611	1.00	607	614	617	620	655	647	847	929	1,124	1,147	1,150	1,189
Retained Earnings	-4.9%	-719	-685	-660	-626	-606	-594	-596	-592	-626	-621	-608	-598	-589	-574	-537	-333	-251	-53.87	-28.34	3.00	50.00
Additional Paid-In Capital	0.3%	1,808	1,803	1,775	1,769	1,487	1,472	1,231	1,224	1,341	1,249	1,243	1,237	1,229	1,225	1,184	1,180	1,174	1,162	1,158	1,096	1,093
Shares Outstanding	0.7%	111	110	111	108	94.00	92.00	90.00	90.00	86.00	85.00	85.00	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	-	-	7.00	16.00	16.00	50.00	46.00
Float	-	-	-	3,400	-	-	-	2,500	-	-	-	1,600	-	-	-	540	-	-	-	600	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	47.7%	89,381	60,521	654	-7,974	35,695	-3,470	13,664	-57,442	66,656	44,501	-24,247	-48,163	-12,851	-20,499	37,666	-20,541	13,187	-16,590	-13,533	-25,709	-24,968
Share Based Compensation	3.7%	10,603	10,222	8,966	10,710	14,631	6,992	7,012	5,346	4,957	4,395	3,653	3,706	4,231	3,164	3,703	3,508	573	5,758	4,750	4,537	5,049
Cashflow From Investing	1.5%	-6,052	-6,145	-8,354	-394,993	-4,456	-254,989	-16,436	16,766	-54,368	-1,798	-5,571	45,951	-2,225	281,679	-7,575	-10,807	-79,174	-11,644	-65,338	-25,478	-135,442
Cashflow From Financing	-125.7%	-84,352	-37,367	23,330	379,729	-10,854	173,081	20,690	-51,376	60,898	641	-35,503	-55,584	-23,916	-13,856	-6,664	32,574	-11,246	96,772	-11,406	-109,665	281,959
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	685	-	-	-	-	-	-

EVH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Income Statement [Abstract]

Revenue

^[1]

$ 1,963,896

$ 1,352,013

$ 907,957

Expenses

Cost of revenue

^[1]

1,503,426

1,035,429

657,551

Selling, general and administrative expenses

^[1]

358,110

269,269

219,499

Depreciation and amortization expenses

123,415

67,195

60,037

Loss on disposal of non-strategic assets

8,107

Right-of-use assets impairment

24,065

Change in fair value of contingent consideration

17,984

(23,522)

13,281

Total operating expenses

2,035,107

1,348,371

950,368

Operating income (loss)

(71,211)

3,642

(42,411)

Interest income

5,256

1,369

407

Interest expense

(54,205)

(15,572)

(25,425)

Gain from equity method investees

1,290

4,569

13,179

Gain on transfer of membership

45,938

Loss on extinguishment/repayment on long-term debt, net

(21,010)

(10,192)

(21,343)

Change in tax receivables agreement liability

(61,982)

(45,950)

Other income (expense), net

(543)

(146)

Loss before income taxes

(202,405)

(62,077)

(29,801)

Provision for (benefit from) income taxes

(89,365)

(43,376)

483

Loss from continuing operations

(113,040)

(18,701)

(30,284)

Loss from discontinued operations, net of tax

^[2]

(463)

(7,317)

Loss before preferred dividends and accretion of Series A Preferred Stock

(113,040)

(19,164)

(37,601)

Dividends and accretion of Series A Preferred Stock

(29,220)

Net (loss) attributable to common shareholders of Evolent Health, Inc. - Basic

(142,260)

(19,164)

(37,601)

Net (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted

$ (142,260)

$ (19,164)

$ (37,601)

Basic and diluted:

Continuing operations, basic (in dollars per share)

$ (1.28)

$ (0.20)

$ (0.35)

Continuing operations, diluted (in dollars per share)

(1.28)

(0.20)

(0.35)

Discontinued operations basic (in dollars per share)

(0.09)

Discontinued operations diluted (in dollars per share)

(0.09)

Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)

(1.28)

(0.20)

(0.44)

Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)

$ (1.28)

$ (0.20)

$ (0.44)

Weighted-average common shares outstanding

Basic (in shares)

111,251

93,699

86,067

Diluted (in shares)

111,251

93,699

86,067

Comprehensive loss

Net loss attributable to common shareholders of Evolent Health, Inc.

$ (142,260)

$ (19,164)

$ (37,601)

Other comprehensive loss, net of taxes, related to:

Foreign currency translation adjustment

(79)

(816)

(84)

Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.

$ (142,339)

$ (19,980)

$ (37,685)

[1]	See Note 20 for amounts attributable to unconsolidated related parties included in these line items.
[2]	Includes $0.5 million and $6.8 million loss on disposal of discontinued operations for the years ended December 31, 2022 and 2021, respectively

EVH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 192,825

$ 188,200

Restricted cash and restricted investments

13,768

14,492

Accounts receivable, net

^[1]

446,749

254,684

Prepaid expenses and other current assets

30,331

20,678

Total current assets

683,673

478,054

Restricted cash and restricted investments

16,864

12,466

Investments in equity method investees

4,895

4,475

Property and equipment, net

78,194

87,874

Right-of-use assets - operating

11,983

49,027

Prepaid expenses and other noncurrent assets

4,028

2,378

Contract cost assets

12,120

17,461

Intangible assets, net

752,009

442,784

Goodwill

1,116,542

722,774

Total assets

2,680,308

1,817,293

Current liabilities:

Accounts payable

^[1]

48,246

57,174

Accrued liabilities

^[1]

149,849

111,198

Operating lease liability - current

9,738

7,122

Accrued compensation and employee benefits

56,385

52,460

Deferred revenue

5,976

5,758

Reserve for claims and performance - based arrangements

404,048

199,730

Total current liabilities

674,242

433,442

Long-term debt, net

597,049

412,986

Other long-term liabilities

3,637

4,744

Tax receivables agreement liability

107,932

45,950

Operating lease liabilities - noncurrent

38,009

56,010

Deferred tax liabilities, net

13,311

4,744

Total liabilities

1,434,180

957,876

Commitments and Contingencies (See Note 11)

Mezzanine Equity

Preferred class A common stock - $0.01 par value; 50,000,000 shares authorized; 175,000 and 0 shares issued, respectively

178,427

Shareholders' Equity

Class A common stock - $0.01 par value; 750,000,000 shares authorized; 115,424,833 and 101,500,558 shares issued, respectively

1,154

1,015

Additional paid-in-capital

1,808,121

1,486,857

Accumulated other comprehensive loss

(1,257)

(1,178)

Retained earnings (accumulated deficit)

(719,194)

(606,154)

Treasury stock, at cost; 1,537,582 shares issued, respectively

(21,123)

Total shareholders' equity

1,067,701

859,417

Total liabilities, mezzanine equity and shareholders' equity

$ 2,680,308

$ 1,817,293

[1]	See Note 20 for amounts attributable to related parties included in these line items.

About Evolent Health Inc

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology, cardiology, and musculoskeletal markets; physician-oriented total cost of care solutions; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

CEO	Mr. Seth Barrie Blackley
WEBSITE	evolenthealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	5100

Evolent Health Inc Frequently Asked Questions

What is the ticker symbol for Evolent Health Inc? What does EVH stand for in stocks?

EVH is the stock ticker symbol of Evolent Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Evolent Health Inc (EVH)?

As of Wed Apr 24 2024, market cap of Evolent Health Inc is 3.38 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers.

What is the fair value of EVH stock?

You can check EVH's fair value in chart for subscribers. The fair value of Evolent Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Evolent Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EVH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Evolent Health Inc a good stock to buy?

The fair value guage provides a quick view whether EVH is over valued or under valued. Whether Evolent Health Inc is cheap or expensive depends on the assumptions which impact Evolent Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVH.

What is Evolent Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, EVH's PE ratio (Price to Earnings) is -29.88 and Price to Sales (PS) ratio is 1.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVH PE ratio will change depending on the future growth rate expectations of investors.